Endogenous glucocorticoids suppress growth and spread of cancer
the ONA take:
According to new findings published in the journal Nature Communications, researchers at the Weizmann Institute of Science in Rehovot, Israel, have found that cancer may grow and spread more during nighttime compared to daytime.
For the study, the researchers wanted to investigate the relationship between the epidermal growth factor receptor (EGFR), a receptor involved with the growth and spread of cancer cells, and the receptor to which glucocorticoids bind. Glucocorticoids are steroid hormones, such as cortisol and cortisone, that play a role in maintaining the body's energy levels during the day and dealing with a stressful situation.
In the study, the researchers found that cell migration is inhibited when the glucocorticoid receptor is bound to its corresponding steroid hormone. Since cell migration is promoted by the EGFR, the researchers wanted to determine whether the relationship between the two receptors is different during nighttime versus daytime. They found that the EGFR was more active during sleep versus waking hours in mice.
Then, the researchers gave lapatinib, a new EGFR inhibitor, to mice at different times of the day. Mice receiving the drug during sleep had significantly decreased tumor burden, suggesting that glucocorticoid levels enhance or inhibit the growth and spread of cancer.
Cancer may grow and spread more during nighttime compared to daytime.
They emerge at night, while we sleep unaware, growing and spreading out as quickly as they can. And they are deadly. In a surprise finding that was recently published in Nature Communications, Weizmann Institute of Science researchers showed that nighttime is the right time for cancer to grow and spread in the body. Their findings suggest that administering certain treatments in time with the body's day-night cycle could boost their efficiency.
This finding arose out of an investigation into the relationships between different receptors in the cell - a complex network that we still do not completely understand. The receptors - protein molecules on the cell's surface or within cells - take in biochemical messages secreted by other cells and pass them on into the cell's interior. The scientists, led by Dr. Mattia Lauriola, a postdoctoral fellow in the research group of Prof. Yosef Yarden of the Weizmann Institute's Biological Regulation Department, working together with Prof. Eytan Domany of the Physics of Complex Systems Department, focused on two particular receptors.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Seeking an Explanation for the Lack of Research Focused in Pediatric Oncology Therapeutics
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|